Blueprint Medicines (BPMC) Tops Q3 EPS by $3.50

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of $11.16, $3.50 better than the analyst estimate of $7.66. Revenue for the quarter came in at $745.1 million versus the consensus estimate of $628.68 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• Argus starts SpaceX at Hold, sees record IPO as a multi-year re-rating challenge